Janssen-Cilag Polska Sp. z o.o.
+ business areaBioPharma R&D+Services
+ annual revenue
2021 – 639,4 mln
2022 – 752,6 mln
2023 – 791,4 mln
+ workforce (estimated if not reported)
2024 - 271
+ depreciation & amortization
2021 – 5,4 mln
2022 – 4,5 mln
2023 – 4,8 mln
Janssen-Cilag Polska focuses on research, development, and commercialization of innovative medicines, and is part of Johnson & Johnson's global pharma network.